Yubo International Biotech Ltd. (YBGJ)

[Potse]

2020 Q4 revenue.....

A couple of observations from the January 14 8-K......

1) Based on the information in that filing, it looks like the earliest the company began generating its first revenues was in April 2020. Gross margin was over 91%, which is quite interesting because included in that revenue was 300 of its nebulizers (medical devices to deliver the inhalant). I have no idea if that margin percentage is just an aberration or if it is indicative of what YBGJ might generate going forward on its product-related revenue. Margin percentages anywhere close to that would be excellent.

Today's amended 8-K gives us the information needed to calculate what 2020 Q4 looked like. Revenue ramped very nicely during that quarter and gross margin remained over 91%. 550 nebulizers were sold during this quarter, compared to 300 in the previous 6 months of revenue generation.

9-month 2020 revenue (January - September): $471,148

Q4 2020 revenue: $882,720